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Abstract
Background
Thyroid nodules are common, and approximately 5% of these nodules are malignant. Pleiotrophin (PTN) is a heparin-binding growth factor which is overexpressed in many cancers.
The expression of PTN in papillary thyroid cancer (PTC) is unknown.
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74 subjects (age 47 ± 12 y, 15 males) who had thyroidectomy with a histological diagnosis:
79 benign nodules and 23 PTCs (10 classic, 6 tall cell, 6 follicular variant and 1 undetermined). Fine-needle aspiration (FNA) samples were obtained ex vivo from surgically
excised tissue and assayed for PTN and thyroglobulin (Tg). Immunohistochemistry (IHC)
was performed on tissue sections. In FNA samples, PTN concentration normalized to Tg
was significantly higher in PTC than in benign nodules (16 ± 6 vs 0.3 ± 0.1 ng/mg, p <
0.001). In follicular variant of PTC (n = 6), the PTN/Tg ratio was also higher than in benign
nodules (1.3 ± 0.6 vs 0.3 ± 0.1 ng/mg, P < 0.001, respectively). IHC showed cytoplasmic
localization of PTN in PTC cells.
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Conclusion
In ex vivo FNA samples, the PTN to thyroglobulin ratio was higher in PTCs, including follicular variant PTC, than in benign thyroid nodules. The findings raise the possibility that measurement of the PTN to Tg ratio may provide useful diagnostic and/or prognostic
information in the evaluation of thyroid nodules.
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Introduction
Thyroid nodules occur frequently in the general population with a prevalence of approximately
3–7% for palpable masses [1, 2]. Approximately 5% of thyroid nodules are malignant [3] and
the most common histological type is papillary thyroid cancer (PTC) [1]. Two major challenges facing clinicians are to distinguish malignant from benign nodules and to identify those
thyroid malignancies that are aggressive [1]. Fine needle aspiration (FNA) cytology represents
the primary preoperative diagnostic tool for the evaluation of thyroid nodules [4], but it is
inconclusive in up to 30% of patients [5]. In particular, follicular variant PTC is difficult to distinguish from benign follicular lesions by cytology [6, 7].
Pleiotrophin (PTN) and midkine (MDK) are related polypeptide heparin-binding growth
factors [8, 9]. PTN and MDK are overexpressed in various human cancers, where they are
thought to promote cell survival, proliferation and angiogenesis, contributing to tumor growth
[10, 11].
We recently reported that the concentration of MDK in FNA samples is elevated in PTCs
compared to benign nodules [12]. In that study, the MDK concentration was normalized to the
thyroglobulin (Tg) concentration, which adjusted for tissue content and also enhanced the separation between malignant and benign samples because of lower Tg concentrations in malignant
nodules. However, neither the MDK concentration nor the MDK/Tg ratio was elevated in the
follicular variant of PTC subgroup [12], limiting the potential diagnostic value of this approach.
PTN was previously reported to be overexpressed in medullary thyroid cancer [13], but the
expression of PTN in PTCs has not been investigated. We hypothesized that PTN concentration and PTN/Tg concentration ratio are higher in PTCs than in benign nodules.

Materials and Methods
Subjects and sample collection
Seventy-four adult subjects (age 47 ± 12 y, 15 males) with thyroid nodules who underwent thyroidectomy at the National Institutes of Health (NIH) Clinical Center were included in the
analysis. Study protocols were approved by National Institute of Diabetes and Digestive and
Kidney Disease Institutional Review Board, and all patients provided written informed consent
to participate in the study. After the thyroid was excised, selected nodules with surrounding tissues were bisected for procurement and then ex vivo FNA was performed by passing a
25-gauge needle into the nodules. The needle was passed 10 to 20 times. No suction was
applied. The tissue within the needle was washed out with 0.5 ml of PBS containing 1% BSA.
The samples were aliquoted and stored immediately at –80 C until assay. Multiple ex vivo FNA
samples (mean, 3.0 samples) were obtained per nodule. We initially attempted to measure
PTN in in vivo FNA washout samples, after the needle contents had been expelled for cytology,
but often found undetectable PTN concentrations, indicating insufficient tissue remaining in
the needle (data not shown).
A total of 103 nodules were sampled. Of these, 62 nodule samples were previously assayed
for MDK concentration and included in a prior report [12].

Pleiotrophin Sandwich ELISA Assay
A PTN sandwich ELISA was developed in our laboratory (see S1 Method for assay details).
The intra-assay CV was 6.9% for high concentration (1.3 ng/mL) and 9% for low concentration
(0.2 ng/mL). The inter-assay CV was 8.8% at 0.2 ng/mL and 12.3% at 0.6 ng/mL. The limit of
detection was 10 pg/mL. There was no cross-reactivity with up to 50 ng/mL of MDK (S1A Fig).
PTN concentrations in PBS containing 1% BSA remained stable in plastic but not glass tubes
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over 2 hours at room temperature and with repeated freeze-thaw cycles (S2 Fig). The assay
showed good parallelism (S3 Fig).

Midkine Sandwich ELISA Assay
MDK sandwich ELISA was performed as previously described using a commercial kit (Biovendor, Czech Republic) with modifications [12]. Intra-assay CV was 3.4% at high concentration
(0.7 ng/mL) and 5.2% at low concentration (0.25 ng/mL). Inter-assay CV was 12.3% at low
concentration. The limit of detection was 0.009 ng/mL. There was no cross-reactivity with up
to 50 ng/mL of PTN (S1B Fig).

Thyroglobulin Assay
50 μL of buffer containing thyroid tissue from an FNA needle was diluted 10-fold in normal
saline and the concentration of Tg was measured with a chemiluminescent immunometric
assay (Immulite 2000XPi, Siemens, UK) according to the manufacturer’s instruction and as
previously described [12].

BRAF mutation analysis
DNA was extracted on a Qiacube semiautomated robotic device (Qiagen, Valencia, CA) using
either the QIAamp DNA Mini Kit (Qiagen) from 17 FNA washout samples and 6 frozen tissue
samples, or the QIAamp DNA FFPE Tissue Kit (Qiagen) for paraffin-embedded tissue sections, according to the instructions of the manufacturer. BRAF T1799A (V600E) mutational
analysis was performed using the PrimePCR ddPCR mutation detection assay (BIO-RAD, Hercules, CA) on a BIO-RAD QX200 droplet digital PCR (ddPCR) system. Each reaction included
10 μl of 2x ddPCR supermix for probes (no dUTP), 1 μl of BRAF V600E primer/probe mix
(FAM), 1 μl of BRAF wild type primer/probe mix (HEX), and 40–100 ng of genomic DNA.
The presence of mutation and the fractional abundance of the mutant allele was determined
with QuantaSoft v.1.7 (BIO-RAD).

Pleiotrophin Immunohistochemistry
Tissues were formalin-fixed, embedded in paraffin, and cut into 5-μm-thick sections which
were deparaffinized and rehydrated in graded alcohol. For antigen retrieval, sections were
placed in citrate buffer at 120°C using a pressuer cooker for 10 minutes. After blocking with
1.5% normal rabbit serum in Tris-buffered saline and Tween 20 (TBST) for 60 minutes at
room temperature, the slides were incubated with a goat polyclonal antibody raised against
human PTN (Cat# AF-252-PB, R&D Systems, Minneapolis, MN) at 1:250 dilution in 1.5%
serum in TBST overnight at 4°C and then visualized with a biotinylated anti-goat IgG secondary antibody (1:200) using the Vectastain ABC (Goat IgG, PK-6105) and DAB kits (Vector
Laboratories, Inc. Burlingame, CA) and counterstained with haematoxylin. Omission of the
primary antiserum was used as a negative control and mouse embryo slides were used as a positive control (S5 Fig). Slides were scanned using a ScanScope XT digital slide scanner and
viewed using ImageScope software (Aperio Technologies, Inc., Vista, CA).

Statistical analysis
All FNA samples from each nodule were averaged to obtain a single mean value. After log transformation, the PTN concentration, Tg concentration and PTN/Tg ratio were compared between
histological groups using t-tests and ANOVA with post-hoc Bonferroni correction for multiple
comparison. The relationship between PTN and Tg was evaluated after log transformation by
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general linear model with nodule number as a covariate. The relationship between PTN/Tg and
MDK/Tg was evaluated by Pearson regression after log transformation. Statistical analysis was
performed using SPSS, version 12 (IBM, NY).

Results
Characteristics of subjects and nodules
A total of 103 nodules from 74 subjects (age 47 ± 12 y, 15 males) were studied by ex vivo FNA at
the time of procurement, immediately after thyroidectomy. Histological examination revealed
23 nodules with PTC (10 classic, 6 tall cell, 6 follicular variant, and 1 undetermined), 1 nodule
with medullary thyroid cancer and 79 benign nodules (72 adenomatoid nodules, 4 follicular adenomas and 3 hyperplastic nodules). Characteristics of nodules with PTC are shown in Table 1.

Association of PTN and Tg concentrations in FNA samples
PTN concentrations were positively associated with Tg concentrations in FNA washout samples from benign nodules (analysis included all individual passes, R2 = 0.04, P < 0.001, S4 Fig).
Since this correlation likely occurred because both PTN and Tg concentrations in the washout
fluid were dependent on the amount of thyroid tissue present in the sample, PTN levels were
normalized to Tg levels as PTN/Tg, ng/mg, to correct for the amount of thyroid tissue.

PTN concentrations and PTN/Tg ratio in ex vivo FNA samples
PTN concentrations in PTC were significantly higher than in benign nodules (0.1 ± 0.01 vs
0.05 ± 0.01 ng/mL, mean ± SEM, p<0.001). PTN concentrations in the subset of follicular variant papillary thyroid cancer (FVPTC) were also higher than in benign nodules (0.12 ± 0.03 vs
0.05 ± 0.01 ng/mL, p<0.001, Fig 1A).
Tg concentrations were lower in PTC than in benign nodules (112 ± 30 vs 926 ± 88 ug/mL,
P < 0.001). In the FVPTC subgroup, Tg concentrations also tended to be lower than in benign
nodules but the difference was not statistically significant (203 ± 80 vs 926 ± 88 ug/mL ng/mL,
P = NS). The ratio of PTN to Tg (ng/mg) was higher in PTC than in benign nodules (16 ± 6 vs
0.3 ± 0.1 ng/mg, P < 0.001, Fig 1B and 1E), and also significantly higher in FVPTC than in
benign nodules (1.3 ± 0.6 vs 0.3 ± 0.1 vs ng/mg, P < 0.001)(Fig 1B). PTN/Tg was also elevated
in the one nodule containing medullary thyroid cancer (2.9 ng/mg).
Among PTCs, there was no difference in PTN concentrations among classic, tall cell variant
and FVPTCs (0.09 ± 0.02, 0.12 ± 0.03 and 0.12 ± 0.03 ng/mL, respectively, P = NS)(Fig 1C).
However, FVPTC had the lowest the PTN/Tg ratios (24.5 ± 11.7, 42.1 ± 23.3 and 1.3 ± 0.6 ng/
mg, respectively, P = 0.06)(Fig 1D).
Of 10 benign nodules with the highest PTN/Tg ratio, 2 occurred in patients with Graves’
disease (2 of 2 subjects with Graves’ disease), 1 in a subject with a follicular adenoma (1 of 4
subjects with follicular adenoma), 1 in a patient with chronic lymphocytic thyroiditis (1 of 3
subjects with chronic lymphocytic thyroiditis), 1 in a benign nodule adjacent to PTC and 5 in
benign nodules without other significant histological findings.
The PTN/Tg ratio had no association with nodule size or the presence of lymph node
metastasis (data not shown).

Association between the PTN/Tg and MDK/Tg and bivariate analysis
Both MDK/Tg and PTN/Tg were measured in 22 PTCs and 77 benign nodules. There was no
association between the PTN/Tg and MDK/Tg among benign nodules. However, there was a
positive correlation between MDK/Tg and PTN/Tg among PTCs (R2 = 0.44, P = 0.001) (Fig 2A).
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Table 1. Characteristics of papillary thyroid cancers (PTCs) studied.
Diagnosis

Tumor size

Metastasisa

2.4 cm

5/6 LN

MDK/Tg(ng/mg)

PTN/Tg (ng/mg)

BRAF mutation

PTC, classic
57.7

2.7

+

0.5 cm

11.8

5.7

-

0.9 cm

64.1

89.1

+

3.0 cm

169.9

85.5

+

1.0 cm

2.4

4.7 cm

1/1 LN

730.0

0.6

-

54.0

+

1.0 cm

3.6

4.6

+

0.7 cm

16.7

0.5

+

NA

0.1

+

37.0

1.8

+

1.8 cm

1/2 LN

1.6 cm
PTC, tall cell variant
5.0 cm

4/33 LN

10.7

+

1.8 cm

1/1 LN

22.4

0.5

+c

1.5 cm

1/1 LN

0.5

0.4

+c

1.5 cm

1/1 LN

0.3

12.4

+c

3.0 cm

2/7 LN

606.0

19.2

+

646.0

59.0

+

2.6 cm

262.0

PTC, follicular variant
0.8 cm

1.5

1.0

+

1.0 cm

0.6

1.3

-d

0.5 cm

1.7

4.0

-

0.5 cm

4.5

0.3

-

0.2

0.5

-

0.9

0.4

-d

2.9

+

1.8 cm

1/2 LN

1.1 cm
PTC, undeterminedb
5.0 cm

103.0

a

LN lymph nodes (number of positive lymph nodes/ total lymph nodes examined).
Histologically, inconclusive but clinically and radiologically malignant

b
c

Different nodules from a subject

d

Different nodules from a subject

doi:10.1371/journal.pone.0149383.t001

A bivariate plot of all nodules with both PTN/Tg and MDK/Tg measured revealed that all
PTCs had MDK/Tg greater than 0.2 ng/mL and PTN/Tg greater than 0. 13 ng/mL (Fig 2B). Of
the 35 nodules that met both these criteria, 23 were malignant (100% of PTC) and 12 were
benign (15% of benign nodules), yielding a sensitivity of 100% and a specificity of 85%.

Association between PTN/Tg ratio and BRAF mutation
Among 23 PTC nodules, 16 had the BRAF V600E mutation. The PTN/Tg ratio tended to be
higher in BRAF-positive than in BRAF-negative nodules but the difference did not reach statistical significance (21.5 ± 7.9 vs 1.8 ± 0.8, P = 0.095).

Confirmation of PTN expression using immunohistochemistry
Immunohistochemical staining of tissue sections revealed that PTN immunostaining was more
intense in those neoplastic thyroid epithelial cells within the PTCs than in the nearby normal
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Fig 1. Pleiotrophin (PTN) concentrations and pleiotrophin/thyroglobulin ratios (PTN/Tg) in benign nodules and papillary thyroid cancer (PTC).
Samples were obtained by ex vivo fine needle aspiration; PTN and Tg were measured by immunoassay. PTN concentrations (mean ± SEM) were higher in
PTC (including all subtypes) and in the subset of follicular variant PTC (FVPTC) than in benign nodules (A). Similarly, PTN/Tg was greater in PTC (including
all subtypes) and in the subset of FVPTC than in benign nodules (B). PTN concentrations did not differ significantly among classic, tall cell variant, and
FVPTC (C). PTN/Tg tended (P = NS) to be lower in FVPTC than in other subtypes (D). Scatterplot showing PTN/Tg values of all nodules. Closed symbols,
PTC; open symbols, benign nodules (E). Values less than 0.001 are displayed as equal to 0.001.
doi:10.1371/journal.pone.0149383.g001
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Fig 2. Association between PTN/Tg and MDK/Tg ratios among all PTC nodules studied (A). PTN/Tg
and MDK/Tg were positively correlated (R2 = 0.44, P = 0.001). Bivariate analysis of PTN/Tg and MDK/Tg
ratios (B). All PTCs had MDK/Tg greater than 0.2 ng/mL (horizontal dashed line) and PTN/Tg greater than
0.13 ng/mL (vertical dashed line). Values less than 0.001 are displayed as equal to 0.001. Closed circles,
PTC; open circles, benign nodules.
doi:10.1371/journal.pone.0149383.g002
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thyroid epithelial cells. (Fig 3A–3C). Some scattered stromal cells in the adjacent connective
tissue also showed immunohistochemical staining. Within thyroid epithelial cells, the PTN
staining was primarily cytoplasmic and perinuclear (Fig 3C).

Discussion
We found that PTN was measurable in FNA samples obtained ex vivo from thyroidectomy
specimens and that the PTN concentrations were higher in PTC than in benign nodules. Similarly, the PTN/Tg ratio was greater in PTC than in benign nodules. We initially chose to use Tg
as a measure of tissue content. However, we found that the level of Tg in samples from PTC was
lower than in samples from benign nodules, suggesting that Tg expression might be lower in
malignant cells, consistent with a prior study [14], and therefore Tg may not simply be a measure of tissue content. However, from a pragmatic standpoint, this effect is fortuitous because
normalization of PTN to Tg enhanced the separation between malignant and benign samples.
PTN expression by PTCs was confirmed by immunohistochemistry. The immunohistochemical findings suggest that PTN is overexpressed by the neoplastic thyroid epithelial cells themselves, primarily in a perinuclear and cytoplasmic localization as reported in other tissues [15–
16]. However, staining for PTN was also observed in the adjacent stromal cells raising the possibility that other cells might also contribute to the elevated PTN measured by ELISA in PTC.
The finding that PTN is elevated in PTC suggests that PTN overexpression may promote
growth of PTCs, which has also been suggested for other cancers, such as ovarian [17], pancreatic [18], glioblastoma [19], prostate cancer [20] and breast cancer [21]. For example, in a
breast cancer model, PTN overexpression stimulated remodeling of the microenvironment,
tumor angiogenesis, and rapid tumor growth [22]. However, in our study, we did not observe
an association between the PTN/Tg ratio and the size of the nodules or the presence of lymph
node metastasis. We also did not find a significant association between the PTN/Tg ratio and
the presence of the BRAF V600E mutation. However, the sample size of our study is insufficient to definitively exclude associations with disease aggressiveness or genetic etiology.
We previously found that the concentration of MDK, a heparin-binding growth factor
related to PTN, was higher in PTC than in benign nodules [12]. In the current study, we found
that MDK/Tg and PTN/Tg were positively correlated in PTCs. However, one important difference is that, in FVPTC, the PTN/Tg was elevated whereas the MDK/Tg showed values overlapping those of benign nodules. This finding is of particular interest because FVPTC is often
difficult to distinguish from benign follicular lesions by cytology, often requiring histological
evaluation [7].
A bivariate plot of PTN/Tg and MDK/Tg showed strong clustering of PTC samples, such
that all malignancies had MDK/Tg greater than 0.2 ng/mg and PTN/Tg greater than 0.13 ng/
mg. Only 15% of benign nodules satisfied both these criteria (Fig 2B). The observation that the
PTN/Tg ratio and the MDK/Tg ratio are elevated in PTC compared to benign nodules raises
the possibility that measurement of PTN, MDK, and Tg in thyroid FNA samples might provide
useful adjunctive diagnostic information to cytologic examination, as has been demonstrated
by RNA profiling [23], mutational analysis [24] and other molecular approaches [25]. However, to establish a clinically useful approach, there are important challenges that would need
to be overcome, many of which reflect limitations in the current study. First, to measure PTN
in FNA washout, sufficient thyroid tissue must be present. Thus, a dedicated FNA pass, separate from those required for cytology, may be required to obtain sufficient tissue as is being
done with the commercially available gene expression classifier test [23]. Alternative possible
approaches include developing a more sensitive PTN assay or washing the expelled needle with
a smaller volume of buffer and performing the assay without dilution. Second, the current
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Fig 3. Immunohistochemical staining for PTN. A) Histological sections containing tall cell variant PTC
were immunostained for PTN (brown color) and counterstained with hematolxylin (purple color).
Immunohistochemical staining was more intense in the neoplastic thyroid epithelial cells within the PTCs
(closed arrows) than in in nearby normal thyroid epithelial cells (open arrows). Some stromal cells in the
adjacent connective tissue also showed immunohistochemical staining. B) Higher magnification of PTC and
normal tissue from the same section as in panel A. C) Immunohistochemical straining of classic PTC that
shows perinuclear location of PTN (arrows). Size bar, 100 μm.
doi:10.1371/journal.pone.0149383.g003

study was performed using FNA samples obtained ex vivo after thyroidectomy. Whether similar data would be observed with in vivo, percutaneous FNA sampling is unknown. We did not
address this question because of the unavailability of dedicated in vivo FNA samples in this
research study. Third, our approach may not be useful in patients with Graves’ disease or
chronic lymphocytic thyroiditis; we observed elevated PTN/Tg ratios in benign nodules within
thyroid glands affected by these autoimmune disease. Fourth, adaptation of these findings into
an adjunctive clinical diagnostic test would require a substantially larger study to determine the
sensitivity and specificity in subjects with indeterminant cytology. The current pilot study demonstrates a novel observation of elevated PTN/Tg in all types of PTC, but was not designed to
rigorously validate a diagnostic test. Our study is designed for a proof-of-concept and used ex
vivo FNA materials. Therefore, ROC analysis is not performed.

Conclusions
In conclusion, our findings indicate that PTN concentrations and the PTN/Tg ratio in ex vivo
FNA samples distinguish PTC from benign lesions, raising the possibility that this strategy
may have adjunctive diagnostic utility to supplement cytology and other existing molecular
methods. However, additional larger studies would be needed to validate this approach.
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